Tissue Regeneration Sciences, Inc is an early stage biotechnology venture founded on the patented tissue regenerative technology of calreticulin. Our mission is to develop and commercialize healing and tissue regenerative technologies to improve patient quality of life.
About Tissue Regeneration Sciences (TRS)
An early stage biotechnology venture founded on the potent novel biotherapeutic, calreticulin, that heals wounds by tissue regeneration.
FIRST INDICATION: Developing the first topical drug treatment for diabetic foot ulcers (DFUs), a serious unmet medical need.
Core Tissue Regeneration Indications
Tissue regeneration of chronic cutaneous wounds including diabetic foot ulcers, pressure ulcers (bed sores), and venous stasis ulcers
Cosmetic soft tissue augmentation for the treatment of fine lines and wrinkles
Ophthalmic ulcers (e.g., corneal abrasions)
Cartilage and bone regeneration
Regeneration of new hair follicles
Orphan indication of sickle cell skin ulcerations
TRS is undertaking preclinical studies to enable filing INDs for initial indications of cutaneous tissue regeneration for chronic and acute wounds, healing of corneal wounds, soft tissue augmentation, and hair follicle neogenesis and to further mechanisms of action of calreticulin in the various indications.
All clinical applications of calreticulin described herein are protected by US and European issued and pending patents.